191 related articles for article (PubMed ID: 38600086)
1. Combination of bazedoxifene with chemotherapy and SMAC-mimetics for the treatment of colorectal cancer.
Dmello RS; Palmieri M; Thilakasiri PS; Doughty L; Nero TL; Poh AR; To SQ; Lee EF; Douglas Fairlie W; Mielke L; Parker MW; Poon IKH; Batlle E; Ernst M; Chand AL
Cell Death Dis; 2024 Apr; 15(4):255. PubMed ID: 38600086
[TBL] [Abstract][Full Text] [Related]
2. Bazedoxifene as a novel GP130 inhibitor for Colon Cancer therapy.
Wei J; Ma L; Lai YH; Zhang R; Li H; Li C; Lin J
J Exp Clin Cancer Res; 2019 Feb; 38(1):63. PubMed ID: 30736824
[TBL] [Abstract][Full Text] [Related]
3. Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
Tian J; Chen X; Fu S; Zhang R; Pan L; Cao Y; Wu X; Xiao H; Lin HJ; Lo HW; Zhang Y; Lin J
Breast Cancer Res Treat; 2019 Jun; 175(3):553-566. PubMed ID: 30852762
[TBL] [Abstract][Full Text] [Related]
4. Repositioning Bazedoxifene as a novel IL-6/GP130 signaling antagonist for human rhabdomyosarcoma therapy.
Xiao H; Bid HK; Chen X; Wu X; Wei J; Bian Y; Zhao C; Li H; Li C; Lin J
PLoS One; 2017; 12(7):e0180297. PubMed ID: 28672024
[TBL] [Abstract][Full Text] [Related]
5. Repurposing the selective estrogen receptor modulator
Thilakasiri P; Huynh J; Poh AR; Tan CW; Nero TL; Tran K; Parslow AC; Afshar-Sterle S; Baloyan D; Hannan NJ; Buchert M; Scott AM; Griffin MD; Hollande F; Parker MW; Putoczki TL; Ernst M; Chand AL
EMBO Mol Med; 2019 Apr; 11(4):. PubMed ID: 30885958
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of GP130/STAT3 and EMT by combined bazedoxifene and paclitaxel treatment in ovarian cancer.
Park SA; Kim LK; Park HM; Kim HJ; Heo TH
Oncol Rep; 2022 Mar; 47(3):. PubMed ID: 35029286
[TBL] [Abstract][Full Text] [Related]
7. Down-regulating IL-6/GP130 targets improved the anti-tumor effects of 5-fluorouracil in colon cancer.
Li S; Tian J; Zhang H; Zhou S; Wang X; Zhang L; Yang J; Zhang Z; Ji Z
Apoptosis; 2018 Jun; 23(5-6):356-374. PubMed ID: 29777330
[TBL] [Abstract][Full Text] [Related]
8. Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy.
Wu X; Cao Y; Xiao H; Li C; Lin J
Mol Cancer Ther; 2016 Nov; 15(11):2609-2619. PubMed ID: 27535971
[TBL] [Abstract][Full Text] [Related]
9. Bazedoxifene Suppresses the Growth of Osteosarcoma Cells by Inhibiting IL-6 and IL-11/GP130 Signaling Pathway.
Wu X; Cao Y; Xiao H; Feng J; Lin J
J Pediatr Hematol Oncol; 2024 Jan; 46(1):8-14. PubMed ID: 37962127
[TBL] [Abstract][Full Text] [Related]
10. Bazedoxifene, a GP130 Inhibitor, Modulates EMT Signaling and Exhibits Antitumor Effects in HPV-Positive Cervical Cancer.
Kim L; Park SA; Park H; Kim H; Heo TH
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445405
[TBL] [Abstract][Full Text] [Related]
11. Blocking IL-6/GP130 Signaling Inhibits Cell Viability/Proliferation, Glycolysis, and Colony Forming Activity in Human Pancreatic Cancer Cells.
Chen X; Tian J; Su GH; Lin J
Curr Cancer Drug Targets; 2019; 19(5):417-427. PubMed ID: 29714141
[TBL] [Abstract][Full Text] [Related]
12. Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface.
Li H; Xiao H; Lin L; Jou D; Kumari V; Lin J; Li C
J Med Chem; 2014 Feb; 57(3):632-41. PubMed ID: 24456369
[TBL] [Abstract][Full Text] [Related]
13. IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis.
Perimenis P; Galaris A; Voulgari A; Prassa M; Pintzas A
BMC Cancer; 2016 Aug; 16():624. PubMed ID: 27520705
[TBL] [Abstract][Full Text] [Related]
14. Discovery of bazedoxifene analogues targeting glycoprotein 130.
Song D; Yu W; Ren Y; Zhu J; Wan C; Cai G; Guo J; Zhang W; Kong L
Eur J Med Chem; 2020 Aug; 199():112375. PubMed ID: 32388278
[TBL] [Abstract][Full Text] [Related]
15. Bazedoxifene exhibits growth suppressive activity by targeting interleukin-6/glycoprotein 130/signal transducer and activator of transcription 3 signaling in hepatocellular carcinoma.
Ma H; Yan D; Wang Y; Shi W; Liu T; Zhao C; Huo S; Duan J; Tao J; Zhai M; Luo P; Guo J; Tian L; Mageta L; Jou D; Zhang C; Li C; Lin J; Lv J; Li S; Lin L
Cancer Sci; 2019 Mar; 110(3):950-961. PubMed ID: 30648776
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Interleukin-6/glycoprotein 130 signalling by Bazedoxifene ameliorates cardiac remodelling in pressure overload mice.
Shi W; Ma H; Liu T; Yan D; Luo P; Zhai M; Tao J; Huo S; Guo J; Li C; Lin J; Zhang C; Li S; Lv J; Lin L
J Cell Mol Med; 2020 Apr; 24(8):4748-4761. PubMed ID: 32164044
[TBL] [Abstract][Full Text] [Related]
17. Modulation of Respiration and Mitochondrial Dynamics by SMAC-Mimetics for Combination Therapy in Chemoresistant Cancer.
Hagenbuchner J; Oberacher H; Arnhard K; Kiechl-Kohlendorfer U; Ausserlechner MJ
Theranostics; 2019; 9(17):4909-4922. PubMed ID: 31410190
[TBL] [Abstract][Full Text] [Related]
18. Molecular subtype-specific responses of colon cancer cells to the SMAC mimetic Birinapant.
Fichtner M; Bozkurt E; Salvucci M; McCann C; McAllister KA; Halang L; Düssmann H; Kinsella S; Crawford N; Sessler T; Longley DB; Prehn JHM
Cell Death Dis; 2020 Nov; 11(11):1020. PubMed ID: 33257690
[TBL] [Abstract][Full Text] [Related]
19. RKIP phosphorylation and STAT3 activation is inhibited by oxaliplatin and camptothecin and are associated with poor prognosis in stage II colon cancer patients.
Cross-Knorr S; Lu S; Perez K; Guevara S; Brilliant K; Pisano C; Quesenberry PJ; Resnick MB; Chatterjee D
BMC Cancer; 2013 Oct; 13():463. PubMed ID: 24098947
[TBL] [Abstract][Full Text] [Related]
20. Differential involvement of gp130 signalling pathways in modulating tobacco carcinogen-induced lung tumourigenesis.
Miller A; Brooks GD; McLeod L; Ruwanpura S; Jenkins BJ
Oncogene; 2015 Mar; 34(12):1510-9. PubMed ID: 24727895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
